Tianjin Medical University Cancer Institute And Hospital

This phase 2 trial tests whether eparlitozoviril, a dual immunotherapy drug, can prevent liver cancer from returning after surgery in patients with microvascular invasion (MVI), a high-risk feature. About 60 participants will receive the drug or active surveillance. The main goal…

This early-stage trial is testing a new cell therapy called GK01 combined with a PD-1 immune checkpoint inhibitor in 15 people with advanced solid tumors (such as lung, stomach, or colorectal cancer). The main goal is to see if the combination is safe and tolerable, while also ch…

This phase 2 trial tests a combination of liver-directed chemotherapy (irinotecan liposome plus 5-FU/LV) with targeted therapy (lenvatinib) and immunotherapy (PD-1 inhibitors) as a first treatment for advanced intrahepatic cholangiocarcinoma, a rare and aggressive bile duct cance…

This study tests a combination of three drugs—fruquintinib (targeted therapy), an immune checkpoint inhibitor (immunotherapy), and TAS-102 (oral chemotherapy)—in people with advanced colorectal cancer that has stopped responding to standard treatments. The goal is to see if this …

This phase 2 trial is testing a combination of three drugs—oral etoposide (chemotherapy), anlotinib (targeted therapy), and envafolimab (immunotherapy)—as a first treatment for elderly patients with extensive small cell lung cancer. The study will enroll 30 participants to see if…

This phase 2 trial is testing a combination of two immunotherapy drugs (sintilimab and ipilimumab) plus chemotherapy (albumin-bound paclitaxel and gemcitabine) as a first treatment for people with advanced bile duct or gallbladder cancer that cannot be removed by surgery. The stu…

This early-phase study tests whether combining two drugs, cadonilimab and regorafenib, can help people with advanced liver cancer whose disease has worsened after at least one prior treatment. About 30 adults will receive the combination to see if tumors shrink and how safe the t…

This study tests a combination of chemotherapy, immunotherapy, and a targeted drug given directly into the liver's blood supply to shrink tumors in people with liver cancer that may be removable with surgery. The goal is to see if this approach can make surgery more effective and…

This study tests whether adding an immunotherapy drug (treprizumab) to standard chemotherapy before surgery can improve outcomes for people with advanced head and neck cancer. About 122 participants will be randomly assigned to receive either the drug combo or chemo alone for thr…

This study tests whether adding the drug surufatinib to standard chemotherapy can help shrink pancreatic tumors enough to allow successful surgery. It involves 29 adults with locally advanced or borderline resectable pancreatic cancer. The main goal is to see how many tumors can …

This study tests a personalized, high-dose radiation therapy (SBRT) for people with early-stage peripheral non-small cell lung cancer who cannot have surgery or choose not to. The goal is to see if this tailored approach controls the tumor and helps patients live longer with fewe…

This trial tests whether an AI-based management platform, called 'Zhiliao Doctor,' can reduce anxiety and depression in 300 breast cancer patients taking CDK4/6 inhibitors at home. Participants are randomly assigned to standard care, the AI platform, or personalized follow-up cal…

This study looks at whether using a small camera (laparoscopy) to see if stomach cancer has spread inside the belly can help doctors choose the best treatment. About 968 people with stage III stomach cancer will be randomly assigned to either standard care or care guided by this …

This study looked back at medical records from 800 patients with unresectable liver cancer who were treated with lenvatinib-based therapy at six hospitals. Researchers analyzed how long patients survived, how well the cancer responded, and any side effects. The goal is to better …

This study reviews medical records from 300 cancer patients to see if the makeup of a tumor's surroundings (the tumor microenvironment) is linked to how well antibody-based therapies work. Researchers will analyze tissue samples and blood markers from patients with seven types of…

This study looks back at medical records from 400 older adults (age 60+) with Hodgkin lymphoma in China. Researchers are collecting information on patient characteristics, treatments, and survival to build a model that can predict how the disease will progress. The goal is to hel…